## Public Health

Adam Gregg LT. GOVERNOR

> Kelly Garcia DIRECTOR

## Influenza Vaccine Information by Age Group 2023-24 Influenza Season

Trade Name	Manufacturer	Presentation	Mercury from Thimerosal (µg per 0.5 mL)	Age Group	Route
Inactivated quad	irivalent (IIV4s),	standard-dose-egg b	ased		
Afluria Quadrivalent	Seqirus	0.5 mL PFS+	0.0	≥ 3 years	IM§
		5.0 mL MDV+	24.5	≥ 6 months	IM§
Fluarix Quadrivalent	GlaxoSmithKline	0.5 mL PFS	0.0	≥ 6 months	IMş
FluLaval Quadrivalent	GlaxoSmithKline	0.5 mL PFS	0.0	≥ 6 months	IM§
Fluzone Quadrivalent	Sanofi Pasteur	0.5 mL PFS**	0.0	≥ 6 months	IM§
		0.5 mL SDV	0.0	≥ 6 months	IM§
		5.0 mL MDV	25	≥ 6 months	IM§
Inactivated quad	irivalent (ccIIV4)	, standard-dose-cell	culture based		
Flucelvax Quadrivalent	Seqirus	0.5 mL PFS	0.0	<u>≥</u> 6 months	IM§
		5.0 mL MDV	25		
Inactivated quad	lrivalent high-do	se, egg based (HD-II	V4)		
Fluzone High-Dose Quadrivalent	Sanofi Pasteur	0.7 mL PFS	0.0	≥ 65 years	IM§
Inactivated quad	lrivalent standar	d-dose, egg based wi	th MF59 adjuvant (allV4)		
Fluad Quadrivalent	Seqirus	0.5 mL PFS	0.0	≥ 65 years	IM§
Recombinant in	luenza vaccine, o	quadrivalent (RIV4)			
Flublock Quadrivalent	Sanofi Pasteur	0.5 mL PFS	0.0	≥ 18 years	IM§
Live, attenuated	influenza vaccin	e, quadrivalent (LAI	V4)- egg based		
FluMist Quadrivalent	AstraZeneca	0.2mL prefilled single- use intranasal sprayer	0.0	2-49 years	NAS

Abbreviations: PFS=prefilled syringe; MDV=multi-dose vial; SDV=single dose vial; IM = intramuscular; NAS=intranasal

\* Vaccination providers should consult FDA-approved prescribing information for 2023–24 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at <a href="https://www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states">https://www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states</a>

§ For adults and older children, the recommended site for intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.

+ The dose volume for Afluria Quadrivalent is 0.25mL for children 6 through 35 months and 0.5mL for persons  $\geq$  3 years. However, 0.25mL prefilled syringes are no longer available. For children aged 6-35 months, a 0.25mL dose must be obtained from a multidose vial.

\*\* Fluzone Quadrivalent is approved for children aged 6 through 35 months at either 0.25 mL or 0.5 mL per dose; however, 0.25 mL prefilled syringes are no longer available. If a prefilled syringe of Fluzone Quadrivalent is used for a child in the age group, the dose volume will be 0.5 mL per dose.

## Adapted from Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023-24 Influenza Season. The full article is available <u>here</u>.